SUPPLEMENT
Q1 2021 — Reconciliation of Non-GAAP Financial Measures
Q1 2021PDF · 4 pages144 KB
Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2021 2020 Net Earnings, after tax- as reported $6,197 $5,796 Pre-tax Adjustments Intangible Asset Amortization expense 1,215 1,118 Litigation expense - 120 Restructuring related 104 118 Acquisition, integration and divestiture related 1 (538) (962) Unrealized (gains)/losses on securities 35 327 Medical Device Regulation 46 14 Tax Adjustments Tax impact on special item adjustments 2 (113) (267) Tax legislation and other tax related (22) (110) Adjusted Net Earnings, after tax $6,924 $6,154 Average shares outstanding (Diluted) 2,672.7 2,671.0 Adjusted net earnings per share (Diluted) $2.59 $2.30 Operational adjusted net earnings per share (Diluted) $2.49 Notes: 1 2 First Quarter Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2 Pharmaeutical brands outside of the U.S. The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 1 of 4 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported (2.3)% 9.6% 10.9% 7.9% U.S. (7.4)% 6.4% 5.4% 3.9% International 2.5% 13.4% 16.2% 12.2% WW Currency 1.0 2.5 2.9 2.4 U.S. - - - - International 2.0 5.5 5.7 4.9 WW Operational (3.3)% 7.1% 8.0% 5.5% U.S. (7.4)% 6.4% 5.4% 3.9% International 0.5% 7.9% 10.5% 7.3% General Surgery Advanced Sterilization Products 0.6 0.2 U.S. 0.0 0.0 International 1.2 0.4 All Other Acquisitions and Divestitures 0.4 0.3 0.1 0.3 U.S. 0.5 (0.2) 0.2 0.0 International 0.4 0.9 0.0 0.5 WW Adjusted Operational (2.9)% 7.4% 8.8% 6.0% U.S. (6.9)% 6.2% 5.6% 3.9% International 0.9% 8.8% 11.8% 8.2% Adjusted Operational Sales Growth FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 4 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income Before Tax by Segment $ 788 770 5,223 3,834 1,629 2,025 (211) (120) 7,429 6,509 % to Sales 22.2% 21.2% 42.8% 34.4% 24.8% 34.1% -0.9% -0.6% 33.3% 31.5% Intangible asset amortization 106 100 856 771 253 247 - - 1,215 1,118 Litigation expense, net - - - 93 - 27 - - - 120 Unrealized loss/(gain) on securities (2) 1 37 314 - 12 - - 35 327 Restructuring related 28 18 20 20 56 80 - - 104 118 Acquisition, integration and divestiture related - - (570) 9 32 (971) - - (538) (962) Medical Device Regulation - - - - 46 14 - - 46 14 Adjusted Income Before Tax by Segment $ 920 889 5,566 5,041 2,016 1,434 (211) (120) 8,291 7,244 % to Sales 26.0% 24.5% 45.6% 45.3% 30.6% 24.2% -0.9% -0.6% 37.1% 35.0% *Estimated as of 04/20/2021 Q1 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 3 of 4 -- First Quarter Acquistion, integration First Quarter April 4, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related and divestiture related (1) Medical Device Regulation April 4, 2021 Non-GAAP Cost of products sold 7,063 $ (1,215) (27) (17) 5,804 Selling, marketing and admin expenses 5,432 (5) 5,427 Research and development expense 3,178 (24) 3,154 Other (Income) / Expense (882) - - (24) 538 (35) (403) Restructuring 53 (53) - Provision for taxes on income 1,232 177 - 20 (101) 8 9 22 1,367 Net Earnings 6,197 1,038 - 84 (437) 27 37 (22) 6,924 First Quarter Acquistion, integration First Quarter March 29, 2020 GAAP Intangible asset amortization Litigation expense, net Restructuring related and divestiture related (1) Medical Device Regulation March 29, 2020 Non-GAAP Cost of products sold 7,062 $ (1,118) (15) (14) 5,915 Other (Income) / Expense (679) (120) (45) 962 (327) (209) Restructuring 58 (58) - Provision for taxes on income 713 146 20 21 3 75 2 110 1,090 Net Earnings 5,796 972 100 97 (965) 252 12 (110) 6,154 Unrealized (loss)/gain on securities Tax legislation and other tax related (1) 2021 primarily includes gains on the divestiture of 2 Pharmaceutical brands outside of the United States. 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition. Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Unrealized (loss)/gain on securities Tax legislation and other tax related -- 4 of 4 --